Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q05823
UPID:
RN5A_HUMAN
Alternative names:
Ribonuclease 4; Ribonuclease L
Alternative UPACC:
Q05823; Q5W0L2; Q6AI46
Background:
2-5A-dependent ribonuclease, also known as Ribonuclease L, plays a pivotal role in the interferon (IFN) antiviral response. It mediates its antiviral effects through various mechanisms, including direct cleavage of viral RNAs, degradation of rRNA to inhibit protein synthesis, induction of apoptosis, and activation of other antiviral genes. Its ability to cleave at specific RNA sequences and regulate mRNA turnover underscores its importance in cellular defense mechanisms.
Therapeutic significance:
Given its crucial role in the antiviral response and regulation of apoptosis, Ribonuclease L is directly associated with hereditary prostate cancer. Understanding the intricate functions of Ribonuclease L could pave the way for innovative therapeutic strategies targeting viral infections and cancer, particularly in developing treatments for hereditary prostate cancer.